The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot

Inclusion Criteria: * Patients 50 or greater * Treated with intraocular injections of Lucentis for at least 6 months and have reached a plateau, defined as 2 consecutive visits (4-6 weeks apart) with no improvement in VA (worse or within one line better) or center subfield thickening (worse or within 30 um better). * Best Corrected Visual Acuity 20/320 or better in the study eye Exclusion Criteria: * Pregnant, lactating females or females of child bearing potential (unless using reliable contraception, i.e. double barrier, surgical sterilization, oral contraceptives, Norplant , intrauterine device (IUD). * Glaucoma or ocular hypertension (defined as IOP \> 21 mmHg or concurrent therapy at screening with IOP-lowering agents) in the study eye * Laser or photodynamic therapy within 12 weeks of screening * Any ocular surgery in the study eye within 12 weeks of screening * Yag capsulotomy in the study eye within 15 days of screening * Treatment with intravitreal, subtenon, or periocular steroid or anti-VEGF therapy other than Lucentis within 6 months prior to enrollment (e.g., triamcinolone injection, Avastin, Macugen.) Systemic treatment with Avastin is also not allowed within 6 months prior to screening or at any time during the study. * Any change in systemic steroid therapy within 3 months of screening * Retinal or choroidal neovascularization due to ocular conditions other than AMD. * Any active viral, fungal or bacterial disease of the cornea or conjunctiva or any history of a potentially recurrent infection which could be activated by treatment with a steroid, (e.g., ocular herpes simplex virus). * Known or suspected hypersensitivity to any of the ingredients of Lucentis, the investigational product or to other corticosteroids. * History of vitrectomy in the study eye * History of uncontrolled IOP elevation with steroid use that did not respond to topical therapy * History or presence of any disease or condition (malignancy) that in the investigator's opinion would preclude study treatment or follow-up * Any lens opacity which impairs visualization of the posterior pole * Participation in another clinical trial within 12 weeks before the screening visit or during the study * Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections.